RESEARCHER PROFILE

Eiman A. Aleem

← Back to London South Bank University

E

London South Bank University

Acute Myeloid Leukemia ResearchCancer-related Molecular PathwaysProtein Kinase Regulation and GTPase SignalingMicrotubule and mitosis dynamicsT-cell and B-cell Immunology

Eiman A. Aleem works in Acute Myeloid Leukemia Research, Cancer-related Molecular Pathways, Protein Kinase Regulation and GTPase Signaling, Microtubule and mitosis dynamics, T-cell and B-cell Immunology. Recorded institutional associations include London South Bank University.

70Publications
2,201Citations
21H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Cdk2 Knockout Mice Are Viable

    2003 · 663 citations
  2. Cdc2–cyclin E complexes regulate the G1/S phase transition

    2005 · 383 citations
  3. Targeting cell cycle regulators in hematologic malignancies

    2015 · 120 citations
  4. Dependence of Cisplatin-Induced Cell Death In Vitro and In Vivo on Cyclin-Dependent Kinase 2

    2006 · 101 citations
  5. IL-7 promotes T cell proliferation through destabilization of p27Kip1

    2006 · 94 citations
  6. Cell Cycle Sibling Rivalry: Cdc2 Versus Cdk2

    2005 · 87 citations
  7. Nanoparticle-mediated cancer cell therapy: basic science to clinical applications

    2023 · 79 citations
  8. β -Glucans and their Applications in Cancer Therapy: Focus on human studies

    2013 · 73 citations
  9. Upregulation of the Insulin Receptor and Type I Insulin-Like Growth Factor Receptor Are Early Events in Hepatocarcinogenesis

    2011 · 62 citations
  10. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

    2017 · 56 citations
  11. Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen

    2012 · 49 citations
  12. Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection

    2011 · 45 citations
  13. Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage

    2017 · 43 citations
  14. Cdk2 as a Master of S phase Entry: Fact or Fake?

    2004 · 39 citations
  15. PRKAR1A Inactivation Leads to Increased Proliferation and Decreased Apoptosis in Human B Lymphocytes

    2006 · 39 citations
  16. Cdk2 and Cdk4 Activities Are Dispensable for Tumorigenesis Caused by the Loss of p53

    2009 · 36 citations
  17. Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism

    2014 · 32 citations
  18. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis

    2018 · 24 citations
  19. Mouse Models of Cell Cycle Regulators: New Paradigms

    2006 · 23 citations
  20. Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications

    2011 · 22 citations
  21. Exopolysaccharide-peptide complex from oyster mushroom (Pleurotus ostreatus) protects against hepatotoxicity in rats

    2020 · 21 citations
  22. CDK2 Is Required By MYC to Induce Apoptosis

    2006 · 20 citations
  23. Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells

    2016 · 18 citations
  24. Highlights on selected growth factors and their receptors as promising anticancer drug targets

    2021 · 13 citations
  25. CDK2 knockdown enhances head and neck cancer cell radiosensitivity

    2013 · 11 citations

← Return to the university profile